Improved Dosing and Administration of Rivaroxaban when Prescribed by a Cardiologist

• Published in: Heart international Vol. 13; no. 1; pp. 24 - 27
• Main Authors: Leiter, Madeline R, Packard, Kathleen A, Qi, Yongyue, Krueger, Steven K
• Format: Journal Article
• Language: English
• Published: Reading Touch Medical Media Limited 01-01-2019
• Subjects: Anticoagulants; Cardiac arrhythmia; Cardiology; Cardiovascular disease; Drug administration; Drug dosages; Prescription drugs
• ISSN: 2036-2579; 2036-2579
• DOI: 10.17925/HI.2019.13.1.24

Rivaroxaban is a direct oral anticoagulant (DOAC) indicated to reduce risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). A discrepancy exists between the recommended dosage and real-world use of DOACs, especially rivaroxaban, thus putting patients at risk of thromboembolic events. Methods: This retrospective study assessed real-world prescribing and patient adherence to dietary requirements during use of rivaroxaban in 116 patients with AF. Associations between prescriber specialty and the correct dosing and administration were assessed using the Chi-Square test. Results: Most rivaroxaban prescriptions were ordered by cardiologists (50.9%). Sixty-nine patients (59.5%) were taking the right dose at the correct time with an adequate meal. Of the 47 (40.5%) taking rivaroxaban incorrectly, 39 (33.6%) had not been administered an adequate meal and eight (6.9%) were not prescribed the correct dose. Compared with other prescribers, patients were most likely to be taking the correct dose and administration when prescribed by cardiologists (72.9% versus 45.6%; p=0.003). Patients were least likely to be taking the correct dose and administration when prescribed by primary care providers (44.4% versus 69.0%; p=0.009). This difference was driven by patients who did not take the treatment with an adequate meal. Conclusion: Inappropriate prescribing, administration and non-adherence to DOACs can have devastating consequences. This highlights the importance of formal systematic education of patients prescribed DOACs across the whole health system. Future studies are warranted to explore the impact of non-adherence to rivaroxaban dietary requirements on clinical outcomes.